| Year |
Citation |
Score |
| 2016 |
Senger DR, Cao S. Diabetic Wound Healing and Activation of Nrf2 by Herbal Medicine. Journal of Nature and Science. 2. PMID 27868087 |
0.01 |
|
| 2016 |
Senger DR, Hoang MV, Kim KH, Li C, Cao S. Anti-inflammatory activity of Barleria lupulina: Identification of active compounds that activate the Nrf2 cell defense pathway, organize cortical actin, reduce stress fibers, and improve cell junctions in microvascular endothelial cells. Journal of Ethnopharmacology. PMID 27660013 DOI: 10.1016/j.jep.2016.09.017 |
0.01 |
|
| 2016 |
Senger DR, Li D, Jaminet SC, Cao S. Activation of the Nrf2 Cell Defense Pathway by Ancient Foods: Disease Prevention by Important Molecules and Microbes Lost from the Modern Western Diet. Plos One. 11: e0148042. PMID 26885667 DOI: 10.1371/journal.pone.0148042 |
1 |
|
| 2015 |
Sabe AA, Potz BA, Elmadhun NY, Liu Y, Feng J, Abid MR, Abbott JD, Senger DR, Sellke FW. Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. The Journal of Thoracic and Cardiovascular Surgery. PMID 26478238 DOI: 10.1016/j.jtcvs.2015.08.101 |
0.01 |
|
| 2015 |
Kim KH, Clardy J, Senger D, Cao S. Chakyunglupulins A and B, two novel 4,8,8-trimethylcyclooct-2-enone derivatives from Barleria lupulina. Tetrahedron Letters. 56: 2732-2734. PMID 26240452 DOI: 10.1016/j.tetlet.2015.04.023 |
1 |
|
| 2015 |
Kim KH, Park YJ, Chung KH, Yip ML, Clardy J, Senger D, Cao S. Iridoid glycosides from Barleria lupulina. Journal of Natural Products. 78: 320-4. PMID 25611215 DOI: 10.1021/np500791a |
1 |
|
| 2011 |
Senger DR, Davis GE. Angiogenesis. Cold Spring Harbor Perspectives in Biology. 3: a005090. PMID 21807843 DOI: 10.1101/cshperspect.a005090 |
1 |
|
| 2011 |
Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood. 117: 1751-60. PMID 21030561 DOI: 10.1182/blood-2010-05-286831 |
1 |
|
| 2011 |
Hoang MV, Nagy JA, Senger DR. Cdc42-mediated inhibition of GSK-3β improves angio-architecture and lumen formation during VEGF-driven pathological angiogenesis. Microvascular Research. 81: 34-43. PMID 20849862 DOI: 10.1016/j.mvr.2010.09.001 |
1 |
|
| 2011 |
Hoang MV, Smith LE, Senger DR. Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. Biochimica Et Biophysica Acta. 1812: 549-57. PMID 20804843 DOI: 10.1016/j.bbadis.2010.08.008 |
1 |
|
| 2010 |
Hoang MV, Nagy JA, Fox JE, Senger DR. Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis. Plos One. 5: e13612. PMID 21049044 DOI: 10.1371/journal.pone.0013612 |
1 |
|
| 2010 |
Hoang MV, Smith LE, Senger DR. Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. Angiogenesis. 13: 269-77. PMID 20809259 DOI: 10.1007/s10456-010-9184-y |
1 |
|
| 2010 |
Savchev SI, Moragianni VA, Senger D, Penzias AS, Thornton K, Usheva A. Follicular fluid-specific distribution of vascular endothelial growth factor isoforms and sFlt-1 in patients undergoing IVF and their correlation with treatment outcomes. Reproductive Sciences (Thousand Oaks, Calif.). 17: 1036-42. PMID 20697141 DOI: 10.1177/1933719110376980 |
1 |
|
| 2010 |
Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor. Molecular Biology of the Cell. 21: 377-9. PMID 20124007 DOI: 10.1091/mbc.E09-07-0591 |
1 |
|
| 2008 |
Davis GE, Senger DR. Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression. Current Opinion in Hematology. 15: 197-203. PMID 18391785 DOI: 10.1097/MOH.0b013e3282fcc321 |
1 |
|
| 2006 |
Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. The Journal of Experimental Medicine. 203: 719-29. PMID 16520388 DOI: 10.1084/jem.20051523 |
1 |
|
| 2006 |
Nagy JA, Senger DR. VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype. Experimental Cell Research. 312: 538-48. PMID 16310771 DOI: 10.1016/j.yexcr.2005.10.017 |
1 |
|
| 2005 |
Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circulation Research. 97: 1093-107. PMID 16306453 DOI: 10.1161/01.RES.0000191547.64391.e3 |
1 |
|
| 2005 |
Hoang MV, Senger DR. In vivo and in vitro models of Mammalian angiogenesis. Methods in Molecular Biology (Clifton, N.J.). 294: 269-85. PMID 15576918 |
1 |
|
| 2004 |
Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF, Bohlen P, Senger DR, Detmar M. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 1111-3. PMID 15132990 DOI: 10.1096/fj.03-1179fje |
1 |
|
| 2004 |
Liu Y, Senger DR. Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 457-68. PMID 15003991 DOI: 10.1096/fj.03-0948com |
1 |
|
| 2004 |
Hoang MV, Whelan MC, Senger DR. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 101: 1874-9. PMID 14769914 DOI: 10.1073/pnas.0308525100 |
1 |
|
| 2003 |
Perruzzi CA, de Fougerolles AR, Koteliansky VE, Whelan MC, Westlin WF, Senger DR. Functional overlap and cooperativity among alphav and beta1 integrin subfamilies during skin angiogenesis. The Journal of Investigative Dermatology. 120: 1100-9. PMID 12787141 DOI: 10.1046/j.1523-1747.2003.12236.x |
1 |
|
| 2003 |
Whelan MC, Senger DR. Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. The Journal of Biological Chemistry. 278: 327-34. PMID 12399469 DOI: 10.1074/jbc.M207554200 |
1 |
|
| 2002 |
Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR. Molecular profiling of angiogenesis markers. The American Journal of Pathology. 161: 35-41. PMID 12107087 DOI: 10.1016/S0002-9440(10)64154-5 |
1 |
|
| 2002 |
Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. The American Journal of Pathology. 160: 195-204. PMID 11786413 |
1 |
|
| 2001 |
Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proceedings of the National Academy of Sciences of the United States of America. 98: 5804-8. PMID 11331770 DOI: 10.1073/pnas.101113998 |
1 |
|
| 2001 |
Ali IU, Senger DR, Smith LE. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology. 57: 143-7. PMID 11295614 DOI: 10.1016/S0090-4295(00)00961-4 |
1 |
|
| 2000 |
Senger DR, Van De Water L. VEGF expression by epithelial and stromal cell compartments: resolving a controversy. The American Journal of Pathology. 157: 1-3. PMID 10880367 DOI: 10.1016/S0002-9440(10)64508-7 |
1 |
|
| 1999 |
Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nature Medicine. 5: 1390-5. PMID 10581081 DOI: 10.1038/70963 |
1 |
|
| 1997 |
Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proceedings of the National Academy of Sciences of the United States of America. 94: 13612-7. PMID 9391074 DOI: 10.1073/pnas.94.25.13612 |
1 |
|
| 1996 |
Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochimica Et Biophysica Acta. 1314: 13-24. PMID 8972713 DOI: 10.1016/S0167-4889(96)00067-5 |
1 |
|
| 1996 |
Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. The American Journal of Pathology. 149: 293-305. PMID 8686754 |
1 |
|
| 1996 |
Senger DR. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. The American Journal of Pathology. 149: 1-7. PMID 8686733 |
1 |
|
| 1995 |
Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology. 26: 86-91. PMID 7821921 DOI: 10.1016/0046-8177(95)90119-1 |
1 |
|
| 1995 |
Claffey KP, Senger DR, Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochimica Et Biophysica Acta. 1246: 1-9. PMID 7811723 DOI: 10.1016/0167-4838(94)00144-6 |
1 |
|
| 1995 |
Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. International Archives of Allergy and Immunology. 107: 233-5. PMID 7542074 DOI: 10.1159/000236988 |
1 |
|
| 1995 |
Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Annals of the New York Academy of Sciences. 760: 83-100. PMID 7540380 DOI: 10.1111/j.1749-6632.1995.tb44622.x |
1 |
|
| 1995 |
Qu-Hong, Nagy JA, Senger DR, Dvorak HF, Dvorak AM. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 43: 381-9. PMID 7534783 |
1 |
|
| 1995 |
Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. The American Journal of Pathology. 146: 157-65. PMID 7531945 |
1 |
|
| 1994 |
Qu-Hong, Brown LF, Senger DR, Geng LL, Dvorak HF, Dvorak AM. Ultrastructural immunogold localization of osteopontin in human gallbladder epithelial cells. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 42: 351-61. PMID 8308252 |
1 |
|
| 1994 |
Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. The American Journal of Pathology. 145: 610-23. PMID 8080043 |
1 |
|
| 1994 |
Gardner HA, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene. 9: 2321-6. PMID 8036014 |
1 |
|
| 1994 |
Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. The Journal of Experimental Medicine. 180: 341-6. PMID 8006592 DOI: 10.1084/jem.180.1.341 |
1 |
|
| 1994 |
Beninati S, Senger DR, Cordella-Miele E, Mukherjee AB, Chackalaparampil I, Shanmugam V, Singh K, Mukherjee BB. Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. Journal of Biochemistry. 115: 675-82. PMID 7916341 |
1 |
|
| 1994 |
Senger DR, Brown LF, Claffey KP, Dvorak HF. Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion & Metastasis. 14: 385-94. PMID 7544775 |
1 |
|
| 1994 |
Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Molecular Biology of the Cell. 5: 565-74. PMID 7522656 |
1 |
|
| 1993 |
Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Research. 53: 2912-8. PMID 8504432 |
1 |
|
| 1993 |
Sioussat TM, Dvorak HF, Brock TA, Senger DR. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Archives of Biochemistry and Biophysics. 301: 15-20. PMID 8442657 DOI: 10.1006/abbi.1993.1109 |
1 |
|
| 1993 |
Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Research. 53: 4727-35. PMID 8402650 |
1 |
|
| 1993 |
Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Reviews. 12: 303-24. PMID 8281615 DOI: 10.1007/BF00665960 |
1 |
|
| 1993 |
Dhanireddy R, Senger D, Mukherjee BB, Mukherjee AB. Osteopontin in human milk from mothers of premature infants Acta Paediatrica, International Journal of Paediatrics. 82: 821-822. PMID 8241638 |
1 |
|
| 1993 |
Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. The American Journal of Pathology. 143: 1255-62. PMID 8238242 |
1 |
|
| 1993 |
Singh K, Deonarine D, Shanmugam V, Senger DR, Mukherjee AB, Chang PL, Prince CW, Mukherjee BB. Calcium-binding properties of osteopontin derived from non-osteogenic sources. Journal of Biochemistry. 114: 702-7. PMID 8113224 |
1 |
|
| 1992 |
Yeo KT, Sioussat TM, Faix JD, Senger DR, Yeo TK. Development of time-resolved immunofluorometric assay of vascular permeability factor. Clinical Chemistry. 38: 71-5. PMID 1733610 |
1 |
|
| 1992 |
Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Molecular Biology of the Cell. 3: 211-20. PMID 1550962 |
1 |
|
| 1992 |
Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF, Rosen S. Vascular permeability factor mRNA and protein expression in human kidney. Kidney International. 42: 1457-61. PMID 1474780 |
1 |
|
| 1992 |
Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Molecular Biology of the Cell. 3: 1169-80. PMID 1421573 |
1 |
|
| 1992 |
Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. The Journal of Experimental Medicine. 176: 1375-9. PMID 1402682 |
1 |
|
| 1992 |
Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, Dvorak AM, van de Water L, Sioussat TM, Senger DR. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Annals of the New York Academy of Sciences. 667: 101-11. PMID 1309029 DOI: 10.1111/j.1749-6632.1992.tb51603.x |
1 |
|
| 1991 |
Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. The American Journal of Pathology. 138: 213-21. PMID 1987767 |
1 |
|
| 1991 |
Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. The Journal of Experimental Medicine. 174: 1275-8. PMID 1940805 |
1 |
|
| 1991 |
Yeo TK, Senger DR, Dvorak HF, Freter L, Yeo KT. Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). Biochemical and Biophysical Research Communications. 179: 1568-75. PMID 1930196 DOI: 10.1016/0006-291X(91)91752-X |
1 |
|
| 1990 |
Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research. 50: 1774-8. PMID 2155059 |
1 |
|
| 1989 |
Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochimica Et Biophysica Acta. 996: 43-8. PMID 2736258 DOI: 10.1016/0167-4838(89)90092-7 |
1 |
|
| 1989 |
Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Research. 9: 1291-9. PMID 2686530 |
1 |
|
| 1989 |
Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochimica Et Biophysica Acta. 948: 305-26. PMID 2465781 DOI: 10.1016/0304-419X(89)90004-8 |
1 |
|
| 1988 |
Senger DR, Perruzzi CA, Ali IU. T24 human bladder carcinoma cells with activated Ha-ras protooncogene: nontumorigenic cells susceptible to malignant transformation with carcinogen. Proceedings of the National Academy of Sciences of the United States of America. 85: 5107-11. PMID 3293049 |
1 |
|
| 1988 |
Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Research. 48: 5770-4. PMID 3167835 |
1 |
|
| 1986 |
Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Research. 46: 5629-32. PMID 3756910 |
1 |
|
| 1985 |
Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Research. 45: 5818-23. PMID 4053052 |
1 |
|
| 1985 |
Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science (New York, N.Y.). 227: 1059-61. PMID 3975602 DOI: 10.1126/science.3975602 |
1 |
|
| 1983 |
Senger DR, Destree AT, Hynes RO. Complex regulation of fibronectin synthesis by cells in culture. The American Journal of Physiology. 245: C144-50. PMID 6869518 |
1 |
|
| 1983 |
Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 302: 714-5. PMID 6835406 DOI: 10.1038/302714a0 |
1 |
|
| 1983 |
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (New York, N.Y.). 219: 983-5. PMID 6823562 |
1 |
|
| 1983 |
Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Reviews. 2: 41-73. PMID 6193869 DOI: 10.1007/BF00046905 |
1 |
|
| 1980 |
Senger DR, Wirth DF, Hynes RO. Transformation-specific secreted phosophoproteins. Nature. 286: 619-21. PMID 7402340 DOI: 10.1038/286619a0 |
1 |
|
| 1980 |
Senger DR, Wirth DF, Bryant C, Hynes RO. Transformation-specific secreted proteins. Cold Spring Harbor Symposia On Quantitative Biology. 44: 651-7. PMID 6933047 |
1 |
|
| 1979 |
Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 16: 885-93. PMID 88265 DOI: 10.1016/0092-8674(79)90103-X |
1 |
|
| 1978 |
Senger DR, Arceci RJ, Gross PR. Histones of sea urchin embryos. Transients in transcription, translation, and the composition of chromatin. Developmental Biology. 65: 416-25. PMID 680370 DOI: 10.1016/0012-1606(78)90037-4 |
1 |
|
| 1978 |
Senger DR, Hynes RO. C3 component of complement secreted by established cell lines. Cell. 15: 375-84. PMID 569023 DOI: 10.1016/0092-8674(78)90006-5 |
1 |
|
| 1978 |
Hynes RO, Ali IU, Destree AT, Mautner V, Perkins ME, Senger DR, Wagner DD, Smith KK. A large glycoprotein lost from the surfaces of transformed cells. Annals of the New York Academy of Sciences. 312: 317-42. PMID 386882 DOI: 10.1111/j.1749-6632.1978.tb16811.x |
1 |
|
| 1978 |
Senger DR, Gross PR. Macromolecule synthesis and determination in sea urchin blastomeres at the sixteen-cell stage. Developmental Biology. 65: 404-15. PMID 79509 DOI: 10.1016/0012-1606(78)90036-2 |
1 |
|
| 1976 |
Arceci RJ, Senger DR, Gross PR. The programmed switch in lysine-rich histone synthesis at gastrulation. Cell. 9: 171-8. PMID 987854 DOI: 10.1016/0092-8674(76)90062-3 |
1 |
|
| 1976 |
Senger DR, Gross PR. Endogenous protein synthesis of the cell-free wheat germ system. Developmental Biology. 53: 128-33. PMID 976595 DOI: 10.1016/0012-1606(76)90215-3 |
1 |
|
| Show low-probability matches. |